AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$HRMY

Budur Kumar sold $1.7M of HRMY

Budur Kumar (CHIEF MEDICAL OFFICER) sold 38,452 shares of Harmony Biosciences Holdings, Inc. (HRMY) at an average of $43.05 ($43.00–$43.05, $1.66M total) across 3 trades over 2026-09-16 to 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Budur Kumar
Published Sep 18, 2026, 8:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HRMY
Bearish
medium confidence
Mentioned
$HRMY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HRMYBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings but is unlikely to move the stock significantly.

02

Market read

Routine insider sale with modest monetary value; limited trading relevance.

03

What to watch

10b5‑1 plan execution may mask timing motives; monitor upcoming clinical data releases.

Relevance 5/10Novelty 4/10Timing: filed Sep 18 2026

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$HRMYBearishMedium confidence
Context

Chief Medical Officer Budur Kumar sold 38,452 shares for $1.66M via a 10b5‑1 plan, reducing his stake to 13,115 shares.

Expected impact

Modest short‑term dip, likely within normal volatility range.

Evidence & confidence

Sale size is modest relative to market cap and follows a pre‑arranged plan, limiting informational weight.

Market effects

Sector

Minimal impact on biotech sector; typical insider sales are common.

Regional

No discernible regional effect.

Global

Limited to investors tracking HRMY.

Counterpoint

What could challenge this read

Sale could be purely liquidity‑driven, not a bearish signal.

Key entities

  • Company
    Harmony Biosciences Holdings, Inc.

    Biotech firm listed on Nasdaq under ticker HRMY.

  • Executive
    Budur Kumar

    Chief Medical Officer of Harmony Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HRMY insider trading history →

Related articles

SEP 3
$HRMYHighAI 8/10

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) stock rose 12.1% since last earnings. The company expects multiple clinical trial data in 2026-2027, including for pitolisant GR and epilepsy treatments. HRMY reaffirmed 2026 revenue guidance of $1B-$1.04B, with Q2 revenues up 21% sequentially. Analysts have upwardly revised estimates, and HRMY has an aggregate VGM Score of A.

finance.yahoo.com2 min
AUG 11
$HRMYMedAI 8/10

Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript

Harmony Biosciences (HRMY) reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, and confirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million ($1.28/diluted share). Cash and investments were $962.5 million as of June 30, 2026. The company also discussed BP-205 clinical data and pipeline timelines.

fool.com10 min
AUG 5
$HRMYMedAI 8/10

Harmony Biosciences Says New Data Supports Neurology Pipeline - Harmony Biosciences Hldgs (NASDAQ:HRMY)

Harmony Biosciences (NASDAQ:HRMY) reported Q2 EPS of $1.28, above a 94-cent consensus, and sales of $261.3 million versus $248.41 million expected. WAKIX net revenue rose 30% to $261.3 million, and HRMY reiterated full-year WAKIX guidance of $1.0B to $1.04B. The company also shared Phase 1 BP-205 SAD data and plans Phase 2 studies from mid-2027.

benzinga.com5 min
AUG 4
$HRMYMed

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class…

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Averag

SEC EDGAR 8-K6 min
JUL 16
$HRMYLow

Harmony Biosciences PREANNOUNCES Record QuarterLY Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 hrmy-20260716xex10d1.htm EX-10.1 ​ ​ ​ Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this “ Agreement ”) is entered into by and between Glenn Reicin (“ Executive ”) and Harmony Biosciences Holdings, Inc. and Harmony Biosciences Management, Inc. (together

SEC EDGAR 8-K2 min
JUN 1
$HRMYMedAI 8/10

Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI

Harmony Biosciences (NASDAQ: HRMY) is a commercial-stage pharma focused on rare neurological diseases, with WAKIX (pitolisant) as its FDA-approved treatment for narcolepsy-related excessive daytime sleepiness and cataplexy. The company reported Q1 2026 total revenue of $215.4 million (+17% YoY) and reaffirmed 2026 net revenue guidance of over $1 billion, citing ongoing WAKIX adoption.

finance.yahoo.com4 min